NCT01554397View on ClinicalTrials.gov

Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

October 13, 2011

Primary Completion Date

June 1, 2021

Study Completion Date

January 1, 2022

Conditions
Cervical Cancer
Interventions
RADIATION

PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT)

IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks with PET-guided Bone Marrow-Sparing

DRUG

Cisplatin

Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks

RADIATION

IMRT

IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks

Trial Locations (7)

33136

University of Miami Miller School of Medicine, Miami

92093

Moores UC San Diego Cancer Center, La Jolla

710032

Xijing Hospital, Xi'an

Unknown

University Hospital Hradec Králové, Hradec Králové

Marie Sklodowska Cancer Center, Gliwice

King Chulalongkorn Hospital, Bangkok

400 012

Tata Memorial Hospital, Pārel

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Diego

OTHER

NCT01554397 - Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer | Biotech Hunter | Biotech Hunter